DILI risk discrimination
AUROC · 96 public test compounds
Identity, fingerprint and scaffold references excluded.
0.952 with identity/fingerprint exclusions only; same 96 cases.
Permeability, distribution, metabolism and safety screening in one workflow. Quantitative outputs and chemical context support compound prioritization.
Strong results across complementary endpoints and evaluation settings.
AUROC · 96 public test compounds
Identity, fingerprint and scaffold references excluded.
0.952 with identity/fingerprint exclusions only; same 96 cases.
MAE, log Papp · 182 compounds
Current alternative physical-mode evaluation on all 182 compounds in the known public development panel.
The public panel informed development. The default ADMET profile uses the hybrid route; its MAE is 0.914 under its separately reported reference-exclusion protocol.
AUROC · 2,467 test compounds
Reference identities, fingerprints and scaffolds excluded. AUPRC: 0.814.
CYP2C9 AUROC 0.835; CYP2D6 0.821. All endpoint metrics and cohorts below.
Clearance and stability estimates
Estimate intrinsic clearance and metabolic-stability class as part of the ADMET workflow.
Assay-specific microsome measurements and reference-exclusion policies are reported in the endpoint table.
Classification accuracy · current panel evaluation
6,713 correct among 7,803 scored; 7,807 requested with four failures. Current system evaluated on the reference panel.
Panel self-exclusion protocol; some equivalent chemical identities can contribute. Reference-excluded fixed-test accuracy: 82.02%.
AUROC · 8,879 compounds
Current reference-panel evaluation also achieves MAE 0.483 pIC50, with all cases scored.
Literal self-exclusion can retain equivalent chemical identities. Reference-excluded fixed-test AUROC: 0.775 on 132 cases.
FluxMateria supports permeability, distribution, metabolism and safety screening with quantitative predictions and chemical context. Each result above names its evaluated mode, cohort and metric. Reference panels, development panels and reference-excluded tests answer different questions; their results are reported with those scopes.
| Endpoint | Measured result | Configuration and evaluation |
|---|---|---|
| Solubility | MAE 1.363 logS; 1,997 cases | Complete route; fixed public test. Test identities, fingerprints and scaffolds excluded. Two fallback results included. |
| Plasma protein binding | MAE 10.517 percentage points; all 559 cases | Percent bound on a 0–100 scale. Fixed public test with identity/fingerprint/scaffold reference exclusions. |
| Intrinsic clearance | Standalone microsome Spearman 0.208 / 0.099; 221 cases | Identity exclusions / additional scaffold exclusions. The profile output under scaffold exclusions gives 0.059. Microsome results do not establish hepatocyte-assay accuracy. |
| Blood-brain barrier | 86.03% accuracy on 7,803 scored; four failures among 7,807 requested | Current reference-panel evaluation under self-exclusion; equivalent identities can contribute. Fixed reference-excluded test: 82.02% accuracy / 83.01% balanced accuracy on all 406. |
| hERG inhibition | AUROC 0.804; MAE 0.483 pIC50; all 8,879 panel cases | Current reference-panel evaluation under literal self-exclusion; equivalent identities can contribute. Fixed reference-excluded test: AUROC 0.7751 standalone / 0.7753 profile, all 132 cases. |
| Caco-2 permeability | Alternative mode MAE 0.281; production profile MAE 0.914 | Current evaluations on 182 cases. The alternative mode uses a known development panel. The profile evaluation excludes identities, fingerprints and test scaffolds from reference support. |
| DILI | AUROC 0.952 / 0.989; the same 96 cases | Complete v4.32 system, identity/fingerprint exclusions / additional scaffold exclusions. All cases scored on the known public test. |
| CYP inhibition | 2C9 / 2D6 / 3A4: AUROC 0.835 / 0.821 / 0.839; AUPRC 0.692 / 0.562 / 0.814 | Current fixed tests of 2,419 / 2,626 / 2,467 cases. Test identities, fingerprints and scaffolds excluded. Each isoform has its own endpoint and metric. |
| Capability | Output available |
|---|---|
| Absorption and permeability | Caco-2 apparent permeability, permeability class and associated screening context. |
| Distribution | Blood-brain barrier classification, aqueous solubility and plasma protein binding. |
| Metabolism | Intrinsic-clearance estimates, metabolic-stability classification and per-isoform CYP inhibition predictions. |
| Safety screening | hERG inhibition estimates and DILI risk with mechanism and exposure context. |
These are measurements of the currently evaluated system. Each product mode has its own input, cohort and reference policy. Reference-assisted panel evaluations and reference-excluded tests remain distinct.
AUROC, AUPRC, classification accuracy, MAE and rank correlation measure different aspects of prediction. TDC ranking comparisons require the specified endpoint, test and metric. Newly selected cases can test transfer to your application.
Choose the properties, input conditions and scoring criteria for your application. A frozen system and partner-selected cases provide a direct product evaluation.